Related Experiment Videos
Endothelin in congestive heart failure
1Medical Research Council, University of Glasgow, Scotland, UK.
Insights
Endothelin (ET) plays a role in congestive heart failure (CHF). Blocking ET actions or generation may offer new therapeutic strategies for CHF patients, potentially improving outcomes beyond current treatments like ACE inhibitors.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Endothelin (ET) peptides exert significant vascular, cardiac, and renal effects.
- These actions are potentially important in the pathophysiology of congestive heart failure (CHF).
- Current CHF treatments, including ACE inhibitors, have limitations, with high morbidity and mortality persisting.
Purpose of the Study:
- To investigate the role of ET in CHF pathophysiology.
- To evaluate the therapeutic potential of anti-ET drugs in CHF.
- To explore novel therapeutic strategies for CHF.
Main Methods:
- In vivo studies using selective and non-selective ET receptor antagonists.
- Investigating the potential of endothelin converting enzyme (ECE) inhibitors.
Main Results:
- ET receptor antagonists are required to clarify ET's role in CHF.
- Anti-ET agents show potential for hemodynamic benefit beyond ACE inhibitors.
- ECE inhibition offers an alternative investigative and therapeutic approach.
Conclusions:
- Blockade of ET actions or generation warrants further investigation for CHF.
- New therapeutic strategies targeting ET may improve CHF management.
- Anti-ET therapies hold promise for patients with high morbidity and mortality from CHF.
Abstract:
The endothelin (ET) family of peptides have potent vascular, cardiac and renal actions which may be of pathophysiological importance in congestive heart failure (CHF). In vivo studies with selective and non-selective ET receptor antagonists are required to clarify the role of ET in the pathophysiology of CHF and determine whether anti-ET drugs may be therapeutically useful in CHF. The impact of angiotensin converting enzyme (ACE) inhibitors on the management of CHF has been such that for any new treatment to be of value it will probably have to offer hemodynamic benefit over and above that already obtained with an ACE inhibitor; anti-ET agents seem to have this potential. The recent formal cloning and characterization of endothelin converting enzyme (ECE) should hasten the development of specific and selective ECE inhibitors and thus provide an alternative investigative, and perhaps therapeutic, tool. Morbidity and mortality from CHF remain unacceptably high even in patients receiving maximal medical therapy, including an ACE inhibitor. Blockade of either the generation (through ECE inhibition) or actions (through receptor blockade) of ET warrant further investigation as potential new therapeutic strategies.